We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusiv... Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. Show more
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the...
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th PR Newswire GERMANTOWN, Md., March 28, 2024 βΒ Inaugural...
Precigen Reports Full Year 2023 Financial Results and Business Updates PR Newswire GERMANTOWN, Md., March 19, 2024 β Β Significant progress made in the development of the PRGN-2012 AdenoVerse...
In Tuesday’s pre-market trading, U.S. index futures are pointing to a decline, reflecting investors’ caution as they analyze revelations from Nvidia’s artificial intelligence...
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis PR...
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th PR Newswire GERMANTOWN, Md., March 5, 2024 GERMANTOWN, Md., March 5, 2024 /PRNewswire/ -- Precigen...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.11 | 8.46153846154 | 1.3 | 1.45 | 1.28 | 715737 | 1.37833512 | CS |
4 | -0.06 | -4.08163265306 | 1.47 | 1.485 | 1.28 | 765050 | 1.38429166 | CS |
12 | 0.01 | 0.714285714286 | 1.4 | 1.785 | 1.28 | 990163 | 1.45974497 | CS |
26 | 0.3 | 27.027027027 | 1.11 | 1.785 | 0.8354 | 1215569 | 1.30296428 | CS |
52 | 0.28 | 24.7787610619 | 1.13 | 1.8799 | 0.8354 | 1290086 | 1.33446769 | CS |
156 | -6.71 | -82.6354679803 | 8.12 | 8.72 | 0.805 | 1366862 | 2.41941382 | CS |
260 | -3.72 | -72.514619883 | 5.13 | 11.1 | 0.805 | 1404681 | 3.43693074 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions